These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
385 related articles for article (PubMed ID: 25524577)
1. LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo. Zhou J; Zheng B; Ji J; Shen F; Min H; Liu B; Wu J; Zhang S Tumour Biol; 2015 May; 36(5):3301-8. PubMed ID: 25524577 [TBL] [Abstract][Full Text] [Related]
2. NG25, a novel inhibitor of TAK1, suppresses KRAS-mutant colorectal cancer growth in vitro and in vivo. Ma Q; Gu L; Liao S; Zheng Y; Zhang S; Cao Y; Zhang J; Wang Y Apoptosis; 2019 Feb; 24(1-2):83-94. PubMed ID: 30515612 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of ovarian cancer cell growth by a novel TAK1 inhibitor LYTAK1. Ying L; Chunxia Y; Wei L Cancer Chemother Pharmacol; 2015 Sep; 76(3):641-50. PubMed ID: 26228528 [TBL] [Abstract][Full Text] [Related]
4. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938 [TBL] [Abstract][Full Text] [Related]
5. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618 [TBL] [Abstract][Full Text] [Related]
6. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer. Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210 [TBL] [Abstract][Full Text] [Related]
7. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. Melisi D; Xia Q; Paradiso G; Ling J; Moccia T; Carbone C; Budillon A; Abbruzzese JL; Chiao PJ J Natl Cancer Inst; 2011 Aug; 103(15):1190-204. PubMed ID: 21743023 [TBL] [Abstract][Full Text] [Related]
8. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells. Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080 [TBL] [Abstract][Full Text] [Related]
9. ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer. Van Schaeybroeck S; Kalimutho M; Dunne PD; Carson R; Allen W; Jithesh PV; Redmond KL; Sasazuki T; Shirasawa S; Blayney J; Michieli P; Fenning C; Lenz HJ; Lawler M; Longley DB; Johnston PG Cell Rep; 2014 Jun; 7(6):1940-55. PubMed ID: 24931611 [TBL] [Abstract][Full Text] [Related]
10. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis. Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137 [TBL] [Abstract][Full Text] [Related]
11. Protein phosphatase 6 activates NF-κB to confer sensitivity to MAPK pathway inhibitors in Zhang H; Read A; Cataisson C; Yang HH; Lee WC; Turk BE; Yuspa SH; Luo J Sci Signal; 2024 May; 17(836):eadd5073. PubMed ID: 38743809 [TBL] [Abstract][Full Text] [Related]
12. Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer. Pek M; Yatim SMJM; Chen Y; Li J; Gong M; Jiang X; Zhang F; Zheng J; Wu X; Yu Q Oncogene; 2017 Aug; 36(35):4975-4986. PubMed ID: 28459468 [TBL] [Abstract][Full Text] [Related]
14. Effects of PHA-665752 and Cetuximab Combination Treatment on In Vitro and Murine Xenograft Growth of Human Colorectal Cancer Cells with KRAS or BRAF Mutations. Jia YT; Yang DH; Zhao Z; Bi XH; Han WH; Feng B; Zhi J; Gu B; Duan Z; Wu JH; Ju YC; Wang MX; Li ZX Curr Cancer Drug Targets; 2018; 18(3):278-286. PubMed ID: 28359236 [TBL] [Abstract][Full Text] [Related]
15. MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling. McNew KL; Whipple WJ; Mehta AK; Grant TJ; Ray L; Kenny C; Singh A Mol Cancer Res; 2016 Dec; 14(12):1204-1216. PubMed ID: 27655129 [TBL] [Abstract][Full Text] [Related]
16. Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models. Morelli MP; Tentler JJ; Kulikowski GN; Tan AC; Bradshaw-Pierce EL; Pitts TM; Brown AM; Nallapareddy S; Arcaroli JJ; Serkova NJ; Hidalgo M; Ciardiello F; Eckhardt SG Clin Cancer Res; 2012 Feb; 18(4):1051-62. PubMed ID: 22173548 [TBL] [Abstract][Full Text] [Related]
17. Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers. Hata AN; Rowley S; Archibald HL; Gomez-Caraballo M; Siddiqui FM; Ji F; Jung J; Light M; Lee JS; Debussche L; Sidhu S; Sadreyev RI; Watters J; Engelman JA Oncogene; 2017 Nov; 36(47):6581-6591. PubMed ID: 28783173 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models. Lee MS; Helms TL; Feng N; Gay J; Chang QE; Tian F; Wu JY; Toniatti C; Heffernan TP; Powis G; Kwong LN; Kopetz S Oncotarget; 2016 Jun; 7(26):39595-39608. PubMed ID: 27167191 [TBL] [Abstract][Full Text] [Related]
19. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer. Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139 [TBL] [Abstract][Full Text] [Related]